130 patients with dysenteric syndrome were treated with Poteseptyl (trimethoprim + Superseptyl), among the 70 (54%) Shigella-positive patients. 70% of the infections were caused by Shigella flexneri strains, 21% by Shigella sonnei, and 9% by Shigella schmitzi. All Shigella strains were found to be sensitive to trimethoprim + sulfonamide. Clinical course was found moderately severe in 52%, mild in 30% and severe in 18%. Severe cases occurred most frequently (in 60%) among the patients with Shigella sonnei infections. A dose of 2 × 2 tablets of Poteseptyl was given for 3 days. The Poteseptyl treatment was clinically successful in 100% and bacteriologically in 98.6%. In cases with bacteriological relapse, the resistance of Shigella strains to Poteseptyl did not increase. On the evidence of our observations, the Poteseptyl (trimethoprim + Superseptyl) treatment of Shigella infections is undoubtedly advisable.

Keywords:
Shigellosis, Trimethoprim and Superseptyl, Poteseptyl
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.